Filing Details
Mereo BioPharma Group plc (NASDAQ:MREO) filed a Form 8-K with the Securities and Exchange Commission on August 19, 2026, disclosing a material event.
8k filedNASDAQ:MREO
Mereo BioPharma Group plc (MREO) Reports Material Event to SEC
Mereo BioPharma Group plc (NASDAQ:MREO) filed a Form 8-K with the Securities and Exchange Commission on August 19, 2026, disclosing a material event.
At publication ·
What changed
Mereo BioPharma Group plc (NASDAQ:MREO) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Mereo BioPharma Group plc filed a Form 8-K with the SEC on August 19, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $0.31 with a market capitalization of $360.8 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Mereo BioPharma Group plc's stock currently trades at $0.31 with a market capitalization of $360.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Mereo BioPharma Group plc's stock.
All SEC filings for Mereo BioPharma Group plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MREO Stock Page
Frequently Asked Questions
Where can I read MREO's SEC filings?
Browse all filings on our MREO SEC filings page.
What types of SEC filings does Mereo BioPharma Group plc file?
Public companies like Mereo BioPharma Group plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.